Clinical trial · Interventional
Ovarian Tissue Cryopreservation in Females Undergoing Procedures That Will Potentially Lead To Loss of Ovarian Function
Ovarian Tissue Cryopreservation As A Means Of Preserving Ovarian Function in Females Undergoing Therapeutic Procedures That Will Potentially Lead To The Irreversible Loss of Ovarian Function
NCT01993732CI-TRIAL-00040057completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to retrieve and cryopreserve ovarian tissue from females undergoing a treatment that may lead to irreversible loss of ovarian function.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Auto Immune Disease | — | UNRESOLVED | — |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Effects of Chemotherapy | — | UNRESOLVED | — |
| Unspecified Complication of Bone Marrow Transplant | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Retrieval and Cryopreservation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Retrieval and Cryopreservation
- description
- Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
- interventionNames
- Procedure: Retrieval and Cryopreservation
Primary outcomes (1)
- measure
- Return of hormones produced by the ovarian tissue
- timeFrame
- 3 months after re-implantation
Secondary outcomes (1)
- measure
- Development of egg(s) appropriate for use in in vitro fertilization
- timeFrame
- Participants will be followed through their reproductive years (until the patient reaches 45 years of age)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 3 Years
Show eligibility criteria text
Inclusion Criteria: * Patient must be female. * Patient must have a disease process where the disease or its treatment adversely affects ovarian function. * Patient must be recommended for this study by their oncologist or specialist. * Patient (or legally authorized representative) must sign an informed consent. Exclusion Criteria: * Patients cannot be male. * Patients must not be HIV positive. * Patient cannot have a poor diagnosis such that she is not expected to survive to adulthood. * Patient cannot have any medical condition that would contraindicate surgery. * Patient cannot have any medical condition that would contraindicate general anesthesia. * Patient cannot have any medical condition that would contraindicate pregnancy.
References
Publications (0)
Data not yet available
No reference posted for this study.